vs
Side-by-side financial comparison of Edwards Lifesciences (EW) and GE HealthCare (GEHC). Click either name above to swap in a different company.
GE HealthCare is the larger business by last-quarter revenue ($5.7B vs $1.6B, roughly 3.5× Edwards Lifesciences). Edwards Lifesciences runs the higher net margin — 23.1% vs 10.3%, a 12.8% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 7.1%). Over the past eight quarters, GE HealthCare's revenue compounded faster (10.7% CAGR vs 9.7%).
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
EW vs GEHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $5.7B |
| Net Profit | $380.7M | $588.0M |
| Gross Margin | 78.0% | 39.7% |
| Operating Margin | 1.8% | 14.5% |
| Net Margin | 23.1% | 10.3% |
| Revenue YoY | 16.7% | 7.1% |
| Net Profit YoY | 6.8% | -18.4% |
| EPS (diluted) | $0.66 | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $5.7B | ||
| Q3 25 | $1.6B | $5.1B | ||
| Q2 25 | $1.5B | $5.0B | ||
| Q1 25 | $1.4B | $4.8B | ||
| Q4 24 | $1.4B | $5.3B | ||
| Q3 24 | $1.4B | $4.9B | ||
| Q2 24 | $1.4B | $4.8B |
| Q1 26 | $380.7M | — | ||
| Q4 25 | $91.2M | $588.0M | ||
| Q3 25 | $291.1M | $446.0M | ||
| Q2 25 | $333.2M | $486.0M | ||
| Q1 25 | $358.0M | $564.0M | ||
| Q4 24 | $385.6M | $721.0M | ||
| Q3 24 | $3.1B | $470.0M | ||
| Q2 24 | $366.3M | $428.0M |
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | 39.7% | ||
| Q3 25 | 77.8% | 38.7% | ||
| Q2 25 | 77.5% | 39.6% | ||
| Q1 25 | 78.7% | 42.1% | ||
| Q4 24 | 78.9% | 42.8% | ||
| Q3 24 | 80.6% | 41.7% | ||
| Q2 24 | 79.9% | 41.4% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 14.5% | ||
| Q3 25 | 19.8% | 12.7% | ||
| Q2 25 | 26.8% | 13.1% | ||
| Q1 25 | 27.9% | 13.2% | ||
| Q4 24 | 22.6% | 15.1% | ||
| Q3 24 | 25.9% | 13.9% | ||
| Q2 24 | 26.8% | 12.6% |
| Q1 26 | 23.1% | — | ||
| Q4 25 | 5.8% | 10.3% | ||
| Q3 25 | 18.7% | 8.7% | ||
| Q2 25 | 21.7% | 9.7% | ||
| Q1 25 | 25.3% | 11.8% | ||
| Q4 24 | 27.8% | 13.6% | ||
| Q3 24 | 226.7% | 9.7% | ||
| Q2 24 | 26.7% | 8.8% |
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | $1.28 | ||
| Q3 25 | $0.50 | $0.98 | ||
| Q2 25 | $0.56 | $1.06 | ||
| Q1 25 | $0.61 | $1.23 | ||
| Q4 24 | $0.65 | $1.58 | ||
| Q3 24 | $5.13 | $1.02 | ||
| Q2 24 | $0.61 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.5B |
| Total DebtLower is stronger | — | $10.0B |
| Stockholders' EquityBook value | — | $10.4B |
| Total Assets | — | $36.9B |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $4.5B | ||
| Q3 25 | $3.8B | $4.0B | ||
| Q2 25 | $4.1B | $3.7B | ||
| Q1 25 | $3.9B | $2.5B | ||
| Q4 24 | $4.0B | $2.9B | ||
| Q3 24 | $4.4B | $3.5B | ||
| Q2 24 | $2.0B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | $10.0B | ||
| Q3 25 | — | $10.3B | ||
| Q2 25 | — | $10.3B | ||
| Q1 25 | — | $8.8B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | — | $9.2B |
| Q1 26 | — | — | ||
| Q4 25 | $10.3B | $10.4B | ||
| Q3 25 | $10.2B | $10.0B | ||
| Q2 25 | $10.5B | $9.7B | ||
| Q1 25 | $10.1B | $9.2B | ||
| Q4 24 | $10.0B | $8.4B | ||
| Q3 24 | $9.5B | $8.3B | ||
| Q2 24 | $7.4B | $7.8B |
| Q1 26 | — | — | ||
| Q4 25 | $13.7B | $36.9B | ||
| Q3 25 | $13.3B | $36.1B | ||
| Q2 25 | $13.5B | $35.5B | ||
| Q1 25 | $13.0B | $33.6B | ||
| Q4 24 | $13.1B | $33.1B | ||
| Q3 24 | $13.0B | $33.9B | ||
| Q2 24 | $10.1B | $31.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.95× | ||
| Q4 24 | — | 1.06× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EW
Segment breakdown not available.
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
